Citi's research report states that WUXI APPTEC's adjusted Net income in the fourth quarter of last year was in line with expectations, and Order growth exceeded expectations. The company expects to maintain a year-on-year revenue increase of 10% to 15% this year, and the adjusted Net income margin will further improve. The company also expects capital expenditures this year to reach 7 billion to 8 billion yuan, mainly for expanding production capacity in China, the USA, and Singapore, and additionally recommends repurchasing 1 billion yuan of A shares. The bank has raised its Net income forecast for WUXI APPTEC for this year and next by 0% to 1%, increasing the Target Price for Listed in Hong Kong from HKD 73.6 to HKD 92.4, while reiterating the 'outperforming the market' rating and listing it as the top choice in the Mainland CRO Sector.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
里昂:上调药明康德目标价至92.4港元 列为内地CRO板块首选
Citi has raised the Target Price of WUXI APPTEC to HKD 92.4 and listed it as the top choice in the Mainland CRO Sector.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 302
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report